vTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at StockNews.com

Posted by on Apr 9th, 2023

Equities researchers at StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Rating) in a research report issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of vTv Therapeutics in a report on Tuesday, March 7th.

vTv Therapeutics Price Performance

VTVT opened at $0.77 on Friday. vTv Therapeutics has a one year low of $0.38 and a one year high of $1.40. The business has a 50 day simple moving average of $0.83 and a two-hundred day simple moving average of $0.84. The firm has a market capitalization of $80.52 million, a price-to-earnings ratio of -3.08 and a beta of -1.17.

vTv Therapeutics (NASDAQ:VTVT – Get Rating) last posted its earnings results on Monday, March 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of $0.01 million for the quarter. As a group, sell-side analysts expect that vTv Therapeutics will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in VTVT. State Street Corp grew its stake in vTv Therapeutics by 268.7% in the second quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 150,228 shares during the period. HBK Sorce Advisory LLC bought a new stake in shares of vTv Therapeutics during the 4th quarter valued at $38,000. Prudential Financial Inc. purchased a new stake in shares of vTv Therapeutics in the 2nd quarter worth about $30,000. Finally, Millennium Management LLC increased its stake in shares of vTv Therapeutics by 12.0% in the 2nd quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 14,845 shares in the last quarter. Hedge funds and other institutional investors own 8.50% of the company’s stock.

vTv Therapeutics Company Profile

(Get Rating)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer.

Featured Articles

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.